Drug Response in Children and Adolescents; From Genes to Treatment
Pharmacogenetics of Common Pediatric and Adolescent Medications
- Global Challenges in Pediatric Pharmacotherapy
In today's world, one of the greatest challenges in healthcare systems is pharmacotherapy for children and adolescents. Children are not just smaller adults; they have unique enzymatic, metabolic, and immune systems that make their responses to medications significantly different from adults. Unfortunately, many drugs are designed and dosed based on clinical studies conducted on adults, and this approach poses serious risks to children.
Statistics show that over 90% of children have at least one high‑risk genetic variant in genes affecting drug response, and about 38% of hospitalized children receive medications whose metabolism is strongly influenced by genetics. However, many physicians and parents are unaware of this reality and continue to use a "one‑dose‑fits‑all" approach, which can lead to treatment ineffectiveness, severe side effects, or even dangerous drug toxicities.
- Benefits of Addressing and Solving These Challenges
Paying attention to genetic differences in drug response in children offers undeniable advantages:
- Increased treatment safety:
Identifying children at risk of severe drug reactions due to genetic variants enables prediction and prevention of adverse reactions.
- Increased treatment efficacy:
By selecting the right medication based on the child's genetic profile, ineffective drug prescriptions can be avoided and treatment success can be maximized.
Targeted prescribing based on genetics prevents wasted spending on ineffective drugs and costs arising from side effects and re‑hospitalizations.
- Reduced stress for parents and physicians:
Knowing that the prescribed medication aligns with the child's genetics brings peace of mind to families and healthcare providers.
- The Role of Genetics in Creating and Managing Drug Challenges in Children
Genetic variants in drug‑metabolizing enzymes (such as the cytochrome P450 family including CYP2D6, CYP2C19, CYP2C9), drug transporter proteins, and drug receptors can cause a standard drug to be improperly metabolized in a child or cause severe side effects. By identifying the child's genetic profile, it becomes possible to choose a more effective and safer drug, adjust the dosage based on metabolic rate, avoid drugs with high risk of serious side effects, and design a personalized treatment plan.
- The Role of PharOmics in Solving These Challenges through DNA Analysis
The PharOmics platform, utilizing the specialized pediatric and adolescent pharmacogenetics panel (Mirrogene), which includes 19 specialized reports on drug response to the most commonly used medications in this age group, enables accurate identification of genetic variants affecting drug metabolism. These reports cover antidepressants and anti‑anxiety medications, proton pump inhibitors, non‑steroidal anti‑inflammatory drugs, thiopurine drugs, antiepileptic drugs, antiemetics, and aminoglycoside antibiotics. PharOmics, through specialized genetic and pharmaceutical counseling, precise result interpretation, and practical recommendations, guides families and physicians on the path to intelligent treatment. The PharOmics Plus service, with continuous updates based on the latest scientific findings, keeps the child's pharmacogenetic report always up to date.